A Decision Support System Based on BI-RADS and Radiomic Classifiers to Reduce False Positive Breast Calcifications at Digital Breast Tomosynthesis: A Preliminary Study

Marco Ali 1,†, Natascha Claudia D’Amico 1,2,†, Matteo Interlenghi 3,4,†, Marina Maniglio 1, Deborah Fazzini 1, Simone Schiaffino 4, Isabella Castiglioni 5,7 and Sergio Papa 1

1 Department of Diagnostic Imaging and Sterotactic Radiosurgery, Centro Diagnostico Italiano S.p.A., Via S. Saint Bon 20, 20147 Milan, Italy; marco.ali@cdi.it (M.A.); nataschaclaudia.damico@cdi.it (N.C.D.); marina.maniglio@cdi.it (M.M.); deborah.fazzini@cdi.it (D.F.); sergio.papa@cdi.it (S.P.)
2 Unit of Computer Systems and Bioinformatics, Department of Engineering, University Campus Bio-Medico di Roma, Via Alvaro del Portillo 20, 00128 Rome, Italy
3 DeepTrace Technologies S.R.L., Via Conservatorio 17, 20122 Milan, Italy; interlenghi@deeptracectech.com
4 Unit of Radiology, IRCCS Policlinico San Donato, Via Morandi 30, 20097 San Donato Milanese, Milan, Italy; schiaffino.simone@gmail.com
5 Department of Science, Technology and Society, Scuola Universitaria Superiore IUSS Pavia, Palazzo del Broletto, Piazza della Vittoria 15, 27100 Pavia, Italy
6 Department of Physics “G. Occhialini”, University of Milan, Bicocca, Piazza della Scienze 3, 20126 Milan, Italy; isabella.castiglioni@unimib.it
7 Institute of Molecular Bioimaging and Physiology, National Research Council, Via F.lli Cervi 93, 20090 Segrate, Milan, Italy
† Correspondence: salvatore@deeptracectech.com
† These authors equally contributed to the work.

Abstract: Digital breast tomosynthesis (DBT) studies were introduced as a successful help for the detection of calcification, which can be a primary sign of cancer. Expert radiologists are able to detect suspicious calcifications in DBT, but a high number of calcifications with non-malignant diagnosis at biopsy have been reported (false positives, FP). In this study, a radiomic approach was developed and applied on DBT images with the aim to reduce the number of benign calcifications addressed to biopsy and to give the radiologists a helpful decision support system during their diagnostic activity. This allows personalizing patient management on the basis of personalized risk. For this purpose, 49 patients showing microcalcifications on DBT images were retrospectively included, classified by BI-RADS (Breast Imaging-Reporting and Data System) and analyzed. After segmentation of microcalcifications from DBT images, radiomic features were extracted. Features were then selected with respect to their stability within different segmentations and their repeatability in test-retest studies. Stable radiomic features were used to train, validate and test (nested 10-fold cross-validation) a preliminary machine learning radiomic classifier that, combined with BI-RADS classification, allowed a reduction in FP of a factor of 2 and an improvement in positive predictive value of 50%.

1. Introduction
Breast calcifications are a diagnostic challenge in mammography interpretation and frequently prompt a needle biopsy [1], being a possible sign of breast cancer (BC) [2]. The introduction of quasi-three-dimensional (3D) acquisition with digital breast tomosynthesis (DBT) has brought considerable advantages in BC detection rates and also, in some studies, lowered the false positive (FP) rate and then the recall (i.e., assessment) rate of patients [3]. In addition, it is worth noting that DBT vacuum-assisted biopsy (VAB) has been recently shown to significantly reduce operation time and radiation exposure [4].
However, accurate visualization of calcifications and discrimination between benign and malignant ones remains an issue for human readers even with DBT. Impressions from initial studies on DBT in the 1990s supposed lower accuracy compared to standard digital mammography (DM), mainly because a cluster of microcalcifications may be visible on different two-dimensional (2D) images, with poor resolution in out-of-focus images and lack of comprehensive cluster visualization [5]. These drawbacks have been overcome using DBT image series and/or DBT-derived synthetic two-dimensional (2D) views, offering a visualization of calcifications similar or even highlighted when compared to standard DM. Notwithstanding these improvements, the malignancy rate of the calcifications addressed to needle biopsy on the basis of DBT remained relatively low, as it was with 2D mammography, with a not-negligible amount of FP, as reported by Lang et al. [6].

Radiomics is a relatively new image-analysis approach allowing the quantitative measurement of high-throughput features from radiological images that are supposed to express the heterogeneity of texture, shape and size of distinct tissue phenotypes correlated to different clinical outcomes [7]. When combined with machine learning algorithms, the radiomic approach was proven able to provide automatic computer-aided classifiers of radiological images. Indeed, radiomic analysis has already been widely implemented in the last few years in various clinical applications [8–10], showing promising results in clinical decision support systems (DSS) and fostering highly tailored medical decision-making in both diagnosis and prognosis [11,12].

Radiomic analysis of DBT (as well as DM) images is supposed to have the intrinsic capability to capture and quantitatively measure those morphometric and textural heterogeneity features of calcifications invisible to the radiologists’ eyes that can be associated with malignancy or poor prognosis, potentially addressing the above-mentioned shortcomings, thus boosting DBT diagnostic performance in women recalled for assessment after calcifications are detected at screening DM [3] or when using DBT as a screening tool, as recently allowed by guidelines issued by the European Commission Initiative on Breast Cancer [13].

While computer-aided detection of calcifications on DBT has been the object of various studies for automatic diagnosis [14–18], few radiomic applications with predictive malignancy or benign role on DBT images have been reported [19,20]. To the best of our knowledge, no radiomic study has been published attaining a higher diagnostic accuracy of radiomics applied to DBT, which would ultimately reduce FP and underpin personalized risk strategies for the management of breast calcifications, eventually considering the not immediate need of biopsy referral but alternative recall for low-risk patients according to a personalized medicine approach.

In this study, we aimed therefore to conduct a radiomic analysis of DBT calcifications with the aim to predict the risk of malignancy among those that would be addressed to biopsy by the radiologists and to give them a helpful DSS during their diagnostic activity.

2. Materials and Methods

2.1. Dataset

In this retrospective, non-consecutive, study, DBT images acquired from patients at our Institution between May 2018 and December 2019 were retrieved, retrospectively evaluated and collected for a radiomic-based classification study to predict malignant vs. benign breast calcifications with low FP ratio. Patient consent was waived by the Ethical Committee due to the retrospective nature of this study. In particular, the study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethical Committee of Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milan (protocol code Tomo-AI; protocol-ID 1666; approved on 14 October 2020).

DBT images were acquired using two full-field digital mammography systems with tomosynthesis (Selenium Dimensions; Hologic Inc., Marlborough, MA, USA). At the time of the study, both the digital mammography systems machines were working within the manufacturers’ specifications and EC quality control regulations. Both the cranio-caudal
and the mediolateral-oblique projection on patients’ breasts were reviewed by an expert breast radiologist with more than 10 years of experience, and the projection in which calcifications were most evident was ultimately analyzed to provide the diagnosis.

Inclusion criteria for the study were: patients with higher than normal risk (e.g., familiar risk) with suspicious microcalcifications detected on DBT by an expert radiologist reader, classified by the radiologist according to the Breast Imaging-Reporting and Data System (BI-RADS) radiological classification [21], diagnosed by the radiologist as “suspected of malignancy” (positive at DBT), then sent to DBT-VAB for histopathological reports and followed up for 1–2 years.

DBT-VAB was performed by three dedicated breast radiologists (with 5–15 years of experience) using a prone breast biopsy system (Affirm Prone and Eviva; Hologic Inc., Marlborough, MA, USA) in combination with a 9-gauge needle for tissue sampling, acquiring at least 12 specimens for each patient.

The number of DBT images were selected in order to fulfill a 2:1 ratio of benign to malignant ratio of calcifications as diagnosed at histopathological reports (and clinical follow up) in order to properly train the model on low false-positive performance.

2.2. Radiologist Classification

For all patients considered in this study (with calcifications found positive at DBT), an expert radiologist reader performed the BI-RADS classification for each calcification on DBT images, fully blinded with respect to the histological results of breast calcifications at DBT-guided VAB (and with respect to the clinical follow up in case of B3).

2.3. Radiomic Classifier

Radiomic methodology was applied to include DBT images of patients, according to the International Biomarker Standardization Initiative (IBSI) guidelines [22].

For this purpose, the TRACE4© radiomic platform was used [23], allowing the whole IBSI-compliant radiomic workflow combined with ensembles of machine learning (ML) classifiers to be obtained in a fully automatic way.

IBSI radiomic workflow included:

(i) the segmentation of the calcification region from each patient DBT image,
(ii) the preprocessing of image content within the segmented region of interest for the radiomic feature extraction,
(iii) the extraction of radiomic features from the segmented region of interest,
(iv) the selection of radiomic features stable with respect to different segmentations (it may occur that different human operators segment the calcification regions of different images) and repeatable in test–retest study,
(v) the use of such stable radiomic features to train, validate, and test different ensembles of ML classifiers in the binary classification task of interest (malignant vs. benign), including the reduction of such stable and repeatable features to not-redundant features in a number that is statistically proper to the number of included image samples of patients.

More specifically:

The segmentation of the calcification region was performed manually, slice by slice, by the expert radiologist, using the TRACE4 Segmentation tool.

The preprocessing of image intensities within the segmented region of interest included resampling to isotropic voxel spacing, using a down-sampling scheme by considering image slice thickness of 1 mm and intensity discretization using a fixed number of 64 bins.

The radiomic features extracted from the segmented region of interest belong to different families: morphology, intensity-based statistics, intensity histogram, gray-level co-occurrence matrix (GLCM), gray-level run length matrix (GLRLM), gray-level size zone matrix (GLSZM), neighborhood gray tone difference matrix (NGTDM), gray-level distance zone matrix (GLDZM), and neighboring gray level dependence matrix (NGLDM).
Their definition, computation and nomenclature are compliant with the IBSI guidelines, except for the features of the family morphology, originally designed for 3D images, which were replaced with ten 2D equivalent features (e.g., 3D features volume and surface were replaced with 2D features area and perimeter, respectively).

Additional details:
- Morphology (10 features). Morphological features (such as area) describe the geometry of an ROI and are based on the voxel contained in the analyzed ROI. For this feature class, IBSI guidelines could not be entirely followed, since 3D images are required while mammography images are 2D images by definition.
- Intensity-based statistics (18 features). Intensity-based statistical features (such as mean intensity, median intensity and intensity variance) describe the intensity distribution within the ROI.
- Intensity histogram (22 features). To calculate intensity histogram features (such as mean discretized intensity, discretized intensity variance and discretized intensity kurtosis), the original intensity distribution is discretized into intensity bins.
- Grey level co-occurrence matrix (100 features). These features are second-order features describing image texture according to pixels’ distribution. For this purpose, a specific matrix was designed to represent in each element the number of times two specific pixels are at a defined distance and angle. The given matrix was used to calculate features such as autocorrelation, cluster shade and cluster prominence [24,25].
- Grey level run length matrix (63 features). These features derive from a support matrix representing the number of times specific pixel/voxel intensity is present in a given direction. Examples for this group of features are grey level non-uniformity, run-length non-uniformity and grey level variance [24,25].
- Grey level size zone matrix (32 features). Features of this group (such as small and large area emphasis, describing the distribution of small and large size zones respectively, size-zone non-uniformity, and zone percentage) quantify the grey level zone of an image, defined as the zone where adjacent (i.e., with distance equal to 1) pixels/voxels share the same intensity [25,26].
- Grey level distance zone matrix (30 features). These features describe how many homogeneous connected areas are present within the Region-Of-Interest (ROI) volume, considering a certain intensity and distance to the shape border [6].
- Neighborhood grey tone difference matrix (10 features). Features from this group (such as coarseness, contrast and busyness) describe spatial changes in the intensity of pixels/voxels in the ROI, analyzing differences between a specific pixel and the surrounding ones. This is accomplished through the creation of a one-dimensional matrix containing—for each pixel intensity value—the summation of the differences between the analyzed pixel and all surrounding neighbors [26,27].
- Neighboring grey level dependence matrix (34 features). These features describe the grey level dependency, defined as the number of voxels within a given distance from the central voxel that they depend on. A neighboring voxel is considered dependent if the difference between that voxel and the central voxel is smaller than a defined threshold. Therefore, the ensuing grey level dependence matrix contains the number of times a specific voxel has \( n \) dependent voxels in its neighborhood [26,27].

These steps were performed using the TRACE4 Radiomic tool. Radiomic features were reported by TRACE4 according to IBSI standards.

The selection of radiomic features that were stable with respect to different segmentations and repeatable in the test–retest study was performed by ICC (ICC > 0.80) when comparing features obtained by data augmentation strategies, (a) randomly manipulating the manual segmentation of the lesion region (performed by the expert operator), and (b) rotating the original images and segmentations. The selected radiomic features (stable and repeatable) were reported by TRACE4.

Two different ensembles of ML classifiers were trained, validated, and tested, for the binary classification task (malignant vs. benign or negative, based on histopathology and
radiological results), selecting stable, reproducible and not redundant features. The oversampling technique for the minority class (malignant) was applied by adaptive synthetic sampling method in order to balance the training.

The first considered ML system was an ensemble of 200 Decision Trees combined with Gini index; the second machine learning system was an ensemble of 100 Support Vector Machines combined with principal components analysis and fisher discriminant ratio. For both systems, a nested K-fold cross-validation method was used (k = 10), and a majority vote rule was applied to assign the binary classes.

For both the classification ensembles, the predictive performances were measured across the different folds (k = 10) in terms of mean Accuracy, Sensitivity, Specificity, AUC, with 95% Confidence Interval and p-value, FP, FN. The classification system with the best performances was chosen as the best classification system for the binary task of interest (malignant vs. benign).

Moreover, a permutation test was performed to assess the statistical significance of the results and to exclude the presence of false discoveries. The permutation test consists in (1) randomly permuting the labels associated with the DBT images, (2) performing training, validation and testing using these permuted labels, and (3) computing classification performance. This procedure is repeated 100 times, thus obtaining a set of 100 “permuted models” and 100 corresponding classification performances. This set of 100 classification performances is then compared to the performance obtained by the non-permuted generated model. A p-value is calculated as the number of “permuted” models that performed better than the “original” model.

These steps were performed by using the TRACE4 Statistics and Modeling tool.

3. Results
3.1. Dataset
In this retrospective study, 49 DBT images including 49 breast calcifications from 49 patients (mean age 51 years, interquartile range 41–81 years) who matched inclusion criteria (positives at DBT for an expert radiologist, see Materials and Methods) were ultimately analyzed and used to build a radiomic-based classifier designed to reduce FP microcalcifications at DBT.

All patients had their calcification histopathological reports available from DBT-guided VAB and 1–2 years follow-up. Histological results at biopsy were malignant (B4 or B5) in 18/49 calcifications (37%) and benign (B2 or B3 with disease-free survival at 1–2 years follow up) in 31/49 (63%), with a benign-to-malignant ratio equal to 1.7, thus matching the criterion of 2:1 benign-to-malignant ratio, according to the inclusion criteria (refer to Materials and Methods). Among the benign calcifications (31), 19 were diagnosed as B2 at biopsy, 4 were diagnosed as B1, and 8 were reported as B3 at biopsy but had a disease-free survival of 12–24 months. Thus, calcification class-labels as “malignant” or “benign” were known and used as the reference standard for the supervised training of the radiomic classifier (refer to Materials and Methods). Table 1 shows the reference standard classification for every single patient included in the study.
Table 1. Reference standard classification (from DBT-guided VAB and follow-up) for each patient included in the study.

| # Patient | Reference Standard Classification DBT-Guided VAB and Follow-Up |
|-----------|---------------------------------------------------------------|
| 1         | Benign (B2)                                                  |
| 2         | Malignant (B5a)                                              |
| 3         | Malignant (B5b)                                              |
| 4         | Benign (B2)                                                  |
| 5         | B3 (Negative at follow up)                                   |
| 6         | Malignant (B5a)                                              |
| 7         | Malignant (B5a)                                              |
| 8         | Malignant (B5a)                                              |
| 9         | Benign (B2)                                                  |
| 10        | Malignant (B5)                                               |
| 11        | Benign (B2)                                                  |
| 12        | Benign (B2)                                                  |
| 13        | Malignant (B5)                                               |
| 14        | Malignant (B4)                                               |
| 15        | Benign (B2)                                                  |
| 16        | Benign (B2)                                                  |
| 17        | Malignant (B5a)                                              |
| 18        | Benign (B2)                                                  |
| 19        | Benign (B2)                                                  |
| 20        | Benign (B2)                                                  |
| 21        | Benign (B1)                                                  |
| 22        | Malignant (B5b)                                              |
| 23        | Malignant (B5a)                                              |
| 24        | Malignant (B5a)                                              |
| 25        | Benign (B2)                                                  |
| 26        | Benign (B2)                                                  |
| 27        | Benign (B1)                                                  |
| 28        | Benign (B2)                                                  |
| 29        | Benign (B2)                                                  |
| 30        | Malignant (B5a)                                              |
| 31        | B3 (Negative at follow up)                                   |
| 32        | Malignant                                                    |
| 33        | Benign (B3)                                                  |
| 34        | Benign (B2)                                                  |
| 35        | Benign (B1)                                                  |
| 36        | B3* (Negative at follow up)                                  |
| 37        | B3* (Negative at follow up)                                  |
| 38        | B3* (Negative at follow up)                                  |
| 39        | Benign (B2)                                                  |
| 40        | Malignant (B5a)                                              |
| 41        | Malignant (B5a)                                              |
| 42        | Malignant (B5b)                                              |
| 43        | Benign (B2)                                                  |
| 44        | B3 (Negative at follow up)                                   |
| 45        | B3* (Negative at follow up)                                  |
| 46        | Benign (B2)                                                  |
| 47        | Benign (B1)                                                  |
| 48        | Malignant (B5a)                                              |
| 49        | Benign (B2)                                                  |

3.2. Radiologist Classification

Table 2 shows, for all 49 patients considered in this study (with calcifications found positives at DBT), the results of the BI-RADS classification for each calcification as performed by an expert radiologist reader on DBT images (refer to Materials and Methods). The
histological results of breast calcifications at DBT-guided VAB (with the clinical follow-up in the case of B3) (reference standard classification) are reported for comparison.

Table 2. Reference standard classification (from DBT-guided VAB and follow-up, and radiological BI-RADS classification for each patient included in the study.

| # Patient | Reference Standard Classification | Radiological BI-RADS Classification |
|-----------|----------------------------------|-------------------------------------|
| 1         | Benign (B2)                      | BI-RADS 3                           |
| 2         | Malignant (B5a)                  | BI-RADS 4                           |
| 3         | Malignant (B5b)                  | BI-RADS 5                           |
| 4         | Benign (B2)                      | BI-RADS 4                           |
| 5         | B3 (Negative at follow up)       | BI-RADS 3                           |
| 6         | Malignant (B5a)                  | BI-RADS 4                           |
| 7         | Malignant (B5a)                  | BI-RADS 4                           |
| 8         | Malignant (B5a)                  | BI-RADS 4                           |
| 9         | Benign (B2)                      | BI-RADS 3                           |
| 10        | Malignant (B5)                   | BI-RADS 4                           |
| 11        | Benign (B2)                      | BI-RADS 3                           |
| 12        | Benign (B2+B3)                   | BI-RADS 4                           |
| 13        | Malignant (B5)                   | BI-RADS 4                           |
| 14        | Malignant (B4)                   | BI-RADS 4                           |
| 15        | Benign (B2)                      | BI-RADS 3                           |
| 16        | Benign (B2)                      | BI-RADS 3                           |
| 17        | Malignant (B5a)                  | BI-RADS 3                           |
| 18        | Benign (B2)                      | BI-RADS 3                           |
| 19        | Benign (B2)                      | BI-RADS 4                           |
| 20        | Benign (B2)                      | BI-RADS 3                           |
| 21        | Benign (B1)                      | BI-RADS 4                           |
| 22        | Malignant (B5b)                  | BI-RADS 4                           |
| 23        | Malignant (B5a)                  | BI-RADS 3                           |
| 24        | Malignant (B5a)                  | BI-RADS 3                           |
| 25        | Benign (B2)                      | BI-RADS 3                           |
| 26        | Benign (B2)                      | BI-RADS 3                           |
| 27        | Benign (B1)                      | BI-RADS 3                           |
| 28        | Benign (B2)                      | BI-RADS 3                           |
| 29        | Benign (B2)                      | BI-RADS 3                           |
| 30        | Malignant (B5a)                  | BI-RADS 4                           |
| 31        | B3 (Negative at follow up)       | BI-RADS 4                           |
| 32        | Malignant (B5a)                  | BI-RADS 5                           |
| 33        | Benign (B3)                      | BI-RADS 3                           |
| 34        | Benign (B2)                      | BI-RADS 4                           |
| 35        | Benign (B1)                      | BI-RADS 3                           |
| 36        | B3* (Negative at follow up)      | BI-RADS 3                           |
| 37        | B3* (Negative at follow up)      | BI-RADS 3                           |
| 38        | B3* (Negative at follow up)      | BI-RADS 4                           |
| 39        | Benign (B2)                      | BI-RADS 3                           |
| 40        | Malignant (B5a)                  | BI-RADS 4                           |
| 41        | Malignant (B5a)                  | BI-RADS 5                           |
| 42        | Malignant (B5b)                  | BI-RADS 5                           |
| 43        | Benign (B2)                      | BI-RADS 4                           |
| 44        | B3 (Negative at follow up)       | BI-RADS 3                           |
| 45        | B3* (Negative at follow up)      | BI-RADS 3                           |
| 46        | Benign (B2)                      | BI-RADS 4                           |
| 47        | Benign (B1)                      | BI-RADS 3                           |
| 48        | Malignant (B5a)                  | BI-RADS 3                           |
| 49        | Benign (B2)                      | BI-RADS 4                           |
Among the calcifications classified as BI-RADS 4 or 5 (26), 12 were benign (FP) at DBT-guided VAB, and 14 were malignant (true positives, TP). Among those classified as BI-RADS 3 (23), 19 were benign (FP) and 4 were malignant (TP). An overall Positive Predictive Value (PPV) of 37% (18/49) was found from the radiologist assessment (31 FP, refer to Table 3). However, PPV was 54% for BI-RADS 4 or 5 and only 17% for BI-RADS 3.

Table 3. Reference standard and radiologist classification results of the tested patients. Number of true positive (TP) and false positive (FP).

| Malignant at Reference Standard | Benign at Reference Standard |
|--------------------------------|-------------------------------|
| Positives at radiologist classification | 18 TP | 31 FP |

3.3. Radiomic Classification

Figure 1A,B shows, as representative examples, two ROIs manually segmented by the expert radiologist on two different DBT images for two calcifications then diagnosed as a malignant lesion and benign cancer lesion, respectively, at their histopathological reports (DBT-guided VAB).

A total of 319 radiomic features compliant with IBSI guidelines [23,24] were extracted from each ROI similarly segmented over the 49 breast calcifications on their DBT images (refer to Materials and Methods). The list, nomenclature and values of such radiomic features are reported in Supplementary file S1 for the above-mentioned representative patient with malignant calcification.

Among the 319 radiomic features, 150 were found stable considering different segmentation perturbations originating from the segmentations defined by the expert radiologist, and the test–retest study (intra-class correlation coefficient > 0.8) (refer to Materials and Methods). Stable features were found belonging to the following sub-groups: morphology (7 features), intensity-based statistics (16 features), intensity histogram (7 features), grey level co-occurrence matrix (54 features), grey level run length matrix (18 features), grey level size zone matrix (10 features), grey level distance zone matrix (20 features), neigh-
borhood grey tone difference matrix (6 features), and neighboring grey level dependence matrix (12 features). The list, nomenclature and values of the 150 stable radiomic features are reported in Supplementary file S2 for the above-mentioned representative patient with malignant calcification.

The best ensemble of machine learning (ML) classifiers (refer to Materials and Methods), supervised-trained (by the reference standard labels of malignant or benign) using the 150 stable features to classify benign calcifications versus malignant calcifications (refer to Materials and Methods), was found to have an ensemble of 200 Decision Trees combined with Gini index. Such radiomic classifier achieved, in testing, an Accuracy, Sensitivity, Specificity, AUC, PPV and Negative Predictive Value (NPV) of 0.82 (95% Confidence Interval 0.69–0.92), 0.78 (0.52–0.94), 0.85 (0.68–0.95), 0.80 (0.67–0.90), 0.74 (0.49–0.91), and 0.88 (0.71–0.96), according to a nested 10-fold cross-validation classification (see Table 4 for a summary of the performances and Figure 2 for ROC-AUC).

Table 4. Performances obtained in testing the best ensemble of machine learning radiomic classifiers for benign calcifications versus malignant calcification. Performances are reported as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and Area Under the Curve (AUC), (95% Confidence Interval), * = p-value < 0.05, ** = p-value > 0.005.

| Sensitivity | Specificity |
|-------------|-------------|
| 0.78 [0.52–0.94] | 0.85 [0.68–0.95] |
| PPV         | NPV         |
| 0.74 [0.49–0.91] | 0.88 [0.71–0.96] |
| Accuracy    | AUC         |
| 0.82 * [0.69–0.92] | 0.80 ** [0.67–0.90] |

Figure 2. ROC-AUC obtained in testing the radiomic classifiers.

Permutation test showed a $p < 0.005$ for the presence of false discoveries with respect to Accuracy, Specificity, AUC, and PPV, and a $p = 0.02$ for NPV. No statistical significance was found for Sensitivity ($p = 0.1$).

Radiomic classification results are reported in Table 5, for each tested patient (with reference standard classification from DBT-guided VAB and follow-up reported for comparison), and in Table 6, for all tested patients, in terms of True Positive (TP), False Positive (FP), True Negative (TN) and False Negative (FN).
Table 5. Reference standard classification (from DBT-guided VAB and follow-up), and radiomic classification, for each single patient included in the study.

| # Patient | Reference Standard Classification | Radiomic Classification |
|-----------|----------------------------------|-------------------------|
| 1         | Benign (B2)                       | Malignant               |
| 2         | Malignant (B5a)                   | Malignant               |
| 3         | Malignant (B5b)                   | Malignant               |
| 4         | Benign (B2)                       | Benign                  |
| 5         | B3 (Negative at follow up)        | Benign                  |
| 6         | Malignant (B5a)                   | Malignant               |
| 7         | Malignant (B5a)                   | Malignant               |
| 8         | Malignant (B5a)                   | Malignant               |
| 9         | Benign (B2)                       | Benign                  |
| 10        | Malignant (B5)                    | Malignant               |
| 11        | Benign (B2)                       | Benign                  |
| 12        | Benign (B2+B3)                    | Benign                  |
| 13        | Malignant (B5)                    | Benign                  |
| 14        | Malignant (B4)                    | Benign                  |
| 15        | Benign (B2)                       | Malignant               |
| 16        | Benign (B2)                       | Benign                  |
| 17        | Malignant (B5a)                   | Malignant               |
| 18        | Benign (B2)                       | Benign                  |
| 19        | Benign (B2)                       | Benign                  |
| 20        | Benign (B2)                       | Benign                  |
| 21        | Benign (B1)                       | Benign                  |
| 22        | Malignant (B5b)                   | Malignant               |
| 23        | Malignant (B5a)                   | Malignant               |
| 24        | Malignant (B5a)                   | Malignant               |
| 25        | Benign (B2)                       | Benign                  |
| 26        | Benign (B2)                       | Malignant               |
| 27        | Benign (B1)                       | Benign                  |
| 28        | Benign (B2)                       | Benign                  |
| 29        | Benign (B2)                       | Benign                  |
| 30        | Malignant (B5a)                   | Malignant               |
| 31        | B3 (Negative at follow up)        | Benign                  |
| 32        | Malignant (B5a)                   | Malignant               |
| 33        | Benign (B3)                       | Benign                  |
| 34        | Benign (B2)                       | Malignant               |
| 35        | Benign (B1)                       | Benign                  |
| 36        | B3* (Negative at follow up)       | Benign                  |
| 37        | B3* (Negative at follow up)       | Benign                  |
| 38        | B3* (Negative at follow up)       | Benign                  |
| 39        | Benign (B2)                       | Malignant               |
| 40        | Malignant (B5a)                   | Malignant               |
| 41        | Malignant (B5a)                   | Benign                  |
| 42        | Malignant (B5b)                   | Benign                  |
| 43        | Benign (B2)                       | Benign                  |
| 44        | B3 (Negative at follow up)        | Benign                  |
| 45        | B3* (Negative at follow up)       | Benign                  |
| 46        | Benign (B2)                       | Benign                  |
| 47        | Benign (B1)                       | Benign                  |
| 48        | Malignant (B5a)                   | Malignant               |
| 49        | Benign (B2)                       | Benign                  |

As more important results of our study that may impact the management of the patients, we can observe from Table 6 that there are only six calcifications classified by our radiomic classifier as FP, showing a reduction of a factor of 5 in FP with respect to radiological classification (31 FP, Table 3). Among these six FP, we did not find BI-RADS 3 (from the total of 23 BI-RADS 3), proving that such a radiomic classifier could be effective.
in reducing FP in this class for radiologists. The overall Positive Predictive Value (PPV) of our radiomic classifier was 70% (14/20).

Table 6. Reference standard and radiomic classification results of the tested patients. Number of true positive (TP), true negative (TN), false positive (FP) and false negative (FN).

| Malignant at Reference Standard | Benign at Reference Standard |
|--------------------------------|-----------------------------|
| Malignant at radiomic classification | 14 TP 6 FP |
| Benign at radiomic classification | 4 FN 25 TN |

However, due to non-negligible FN (4) (error = 4/31 = 19%), our radiomic classifier cannot be used as an automatic reader of DBT images, at least in this preliminary state. However, in combination with an expert radiologist reading and classification, it may be used to reduce FP in the BI-RADS 3 class and to stratify the risk.

According to such a combined approach, we defined the following DSS for the BI-RADS 3 class:

1. if the radiologist reader classifies a breast calcification as BI-RADS 3 AND the radiomic classifier classifies as BENIGN -> DSS predicts low risk of malignancy;
2. if the radiologist reader classifies a breast calcification as BI-RADS 3 AND the radiomic classifier classifies as MALIGNANT -> DSS predicts a high risk of malignancy;
3. if the radiologist reader classifies a breast calcification as BI-RADS 4 or 5 -> DSS assigns a high risk of malignancy.

Overall, there were 15 FP for our DSS; thus reduced by a factor of 2 with respect to FP from radiological classification (31). The overall PPV was 54.5% (18/33), improving by 50% the PPV performance of the radiologist (37%) (refer to Table 7 for detailed results and Table 8 for the confusion matrix summarizing the reference-standard and DSS-classification results of the tested patients).

Table 7. Reference standard classification (from DBT-guided VAB and follow-up, and DSS classification, for each single patient included in the study).

| # Patient | DBT-Guided VAB and Follow-Up (Reference Standard Classification) | DSS Classification |
|-----------|---------------------------------------------------------------|--------------------|
| 1         | Benign (B2)                                                   | High risk of malignancy |
| 2         | Malignant (B5a)                                               | High risk of malignancy |
| 3         | Malignant (B5b)                                               | High risk of malignancy |
| 4         | Benign (B2)                                                   | High risk of malignancy |
| 5         | B3 (Negative at follow up)                                    | Low risk of malignancy |
| 6         | Malignant (B5a)                                               | High risk of malignancy |
| 7         | Malignant (B5a)                                               | High risk of malignancy |
| 8         | Malignant (B5a)                                               | High risk of malignancy |
| 9         | Benign (B2)                                                   | Low risk of malignancy |
| 10        | Malignant (B5)                                                | High risk of malignancy |
| 11        | Benign (B2)                                                   | Low risk of malignancy |
| 12        | Benign (B2+B3)                                                | High risk of malignancy |
| 13        | Malignant (B5)                                                | High risk of malignancy |
| 14        | Malignant (B4)                                                | High risk of malignancy |
| 15        | Benign (B2)                                                   | High risk of malignancy |
| 16        | Benign (B2)                                                   | Low risk of malignancy |
| 17        | Malignant (B5a)                                               | High risk of malignancy |
| 18        | Benign (B2)                                                   | Low risk of malignancy |
| 19        | Benign (B2)                                                   | High risk of malignancy |
| 20        | Benign (B2)                                                   | Low risk of malignancy |
### Table 7. Cont.

| # Patient | DBT-Guided VAB and Follow-Up (Reference Standard Classification) | DSS Classification |
|-----------|---------------------------------------------------------------|-------------------|
| 21        | Benign (B1)                                                  | High risk of malignancy |
| 22        | Malignant (B5b)                                              | High risk of malignancy |
| 23        | Malignant (B5a)                                              | High risk of malignancy |
| 24        | Malignant (B5a)                                              | High risk of malignancy |
| 25        | Benign (B2)                                                  | Low risk of malignancy |
| 26        | Benign (B2)                                                  | High risk of malignancy |
| 27        | Benign (B1)                                                  | Low risk of malignancy |
| 28        | Benign (B2)                                                  | Low risk of malignancy |
| 29        | Benign (B2)                                                  | High risk of malignancy |
| 30        | Malignant (B5a)                                              | High risk of malignancy |
| 31        | B3 (Negative at follow up)                                   | High risk of malignancy |
| 32        | Malignant (B5a)                                              | High risk of malignancy |
| 33        | Benign (B3)                                                  | Low risk of malignancy |
| 34        | Benign (B2)                                                  | High risk of malignancy |
| 35        | Benign (B1)                                                  | Low risk of malignancy |
| 36        | B3* (Negative at follow up)                                  | Low risk of malignancy |
| 37        | B3* (Negative at follow up)                                  | Low risk of malignancy |
| 38        | B3* (Negative at follow up)                                  | High risk of malignancy |
| 39        | Benign (B2)                                                  | High risk of malignancy |
| 40        | Malignant (B5a)                                              | High risk of malignancy |
| 41        | Malignant (B5a)                                              | High risk of malignancy |
| 42        | Malignant (B5b)                                              | High risk of malignancy |
| 43        | Benign (B2)                                                  | High risk of malignancy |
| 44        | B3 (Negative at follow up)                                   | Low risk of malignancy |
| 45        | B3* (Negative at follow up)                                  | Low risk of malignancy |
| 46        | Benign (B2)                                                  | High risk of malignancy |
| 47        | Benign (B1)                                                  | Low risk of malignancy |
| 48        | Malignant (B5a)                                              | High risk of malignancy |
| 49        | Benign (B2)                                                  | High risk of malignancy |

### Table 8. Reference standard and DSS classification results of the tested patients. Number of true positive (TP) and false positive (FP).

|                           | Malignant at Reference Standard | Benign or Negative at Reference Standard |
|---------------------------|---------------------------------|----------------------------------------|
| High risk at DSS classification | 18 TP                           | 15 FP                                  |
| Low risk at DSS classification | 0 FN                            | 16 TN                                  |

### 4. Discussion

Radiomics derive multiple quantitative features from single or multiple medical imaging modalities and techniques, highlighting image traits that are not visible to the naked eye and hence potentially significantly augmenting the diagnostic and prognostic power of medical imaging. This quantitative “big data” approach is a relatively new discipline showing possible limitless applications in clinical practice and research [28,29].

Radiomics strengths in oncology, however, until now have been frequently demonstrated for tomographic imaging, being inherently quantitative tools, where radiomics can provide a comprehensive noninvasive characterization of the whole 3D tumor, defining what has been named the radiomics signature of the tumor [7]. Among published studies, radiomics has been increasingly gaining ground to improve cancer diagnosis, monitoring of treatment response and prognosis, also in the field of breast care [30].

In this work, a radiomic classifier was developed for DBT images on suspected breast calcifications to predict associated malignancy at needle biopsy with the particular purpose to reduce FP of DBT. We analyzed a total of 49 breast calcifications detected at DBT as positive, classified by an expert radiologist according to BI-RADS, and ad-
dressed to DBT-guided VAB with known histopathologic characterization and follow up at 1–2 years. We used these supervised associations to train an ensemble of ML classifiers to automatically distinguish malignant from benign cases from their DBT. Such a predictive radiomic classifier achieved an Accuracy, Sensitivity, Specificity, AUC, PPV and NPV of 0.82, 0.78, 0.85, 0.80, 0.74, and 0.88, respectively, according to a nested 10-fold cross-validation classification. A sensitivity of 78% is currently insufficient to avoid immediate referral to VAB only on the basis of our radiomic model. However, since such limited performances have been obtained on a limited cohort of patients, we can expect that our preliminary classifier could increase its predictive power when a larger sample (labeled by histological finding and follow up) could be available.

Concerning the application of radiomics to 2D DM for calcifications, very few papers have been published. Chen et al. [31] proved that a multimodal radiomic model, consisting of radiomic features from both mammography and dynamic contrast-enhanced magnetic resonance imaging (MRI), combined with a random forest classifier, showed a Sensitivity of 83% and a Specificity of 80% at Leave-One-Out validation, performances comparable to those obtained by our single-modality DBT-based radiomic classifier with an ensemble of random forests. Moreover, our performances were validated with a more robust method (nested k-fold cross-validation) and tested also with a permutation test.

In literature, radiomics has been also applied to other mammographic techniques such as contrast-enhanced spectral mammography. Mao et al. [32] published a multicenter study showing that a radiomics nomogram of contrast-enhanced spectral mammography was able to predict axillary lymph node metastasis in breast cancer. Other authors showed correlations between mammographic radiomics features and the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer [33].

A recent study on Chinese patients published by Zhang et al. [34] confirmed the promises of radiomics combined with DBT to distinguish malignant from benign calcifications, showing that, when radiomic features can be extracted from the reconstructed volume of calcifications and integrated into the 2D radiomic features, the model is able to reduce the FP rate up to 20%. To be noted, in our work, the number of FP classified by our radiomic classifier was found reduced by a factor of 5 from the initial number classified by the expert radiologist, thus effectively reducing the risk of inappropriate biopsies. However, we must consider that a reduction in FP rate without a contemporary high NPV (over 98%) has no clinical impact if BI-RADS clinical rules are applied.

In order to account for this, we designed a DSS based on both the radiological classification (BI-RADS) and the low FP rate achieved by our radiomic classifier on suspected breast calcifications classified as BI-RADS 3. The final results of such a DSS were very good (Table 4), showing a reduction by a factor of 2 in FP from the initial expert radiologist, at no cost of FN, and an improvement in the PPV by 50%, suggesting potential in our approach, and further validation of these preliminary results with larger datasets. If confirmed by multicenter studies with large sample size, our DSS could reinforce the decision of BI-RADS 3 category to not send to biopsy but to recall for monitoring or to downscale the diagnostic category from BI-RADS 3 to BI-RADS 2.

Our study has important limitations. First, the retrospective single-center design, which made it difficult to obtain a larger sample size useful to train and independently test both the radiomic classifier and the DSS developed. However, the different examinations were collected using different DBT units; thus, we can consider the performance of our model to be somewhat robust with respect to independent DBT systems. Second, our study suffers from the lack of a temporal and geographical independent dataset to test the developed models. However, we performed a robust nested k-fold cross-validation on the radiomic model to avoid using testing data during training, and, as already highlighted above, a permutation test to assess the statistical significance of our results and to exclude the presence of false discoveries ($p < 0.05$). Third, the non-consecutive enrollment of cases, which does not allow a disease-prevalence interpretation of the PPV and NPV obtained in our work, although they can be compared quantitatively. Fourth, we should
consider that the DBT system guiding the VAB was different from the one used for the first image acquisition and the acquired images. Potential differences between those images could have influenced the choice of the radiologist performing the VAB (site of biopsy, number of samplings). However, we must consider that the aim of the VAB is to sample the target finding identified on the initial DBT images, and a careful breast positioning and repeated comparison with the initial images are performed to obtain a precise tissue sampling allowing a pathological examination to be strictly correlated with the initially detected finding. Moreover, it should be considered that the aim of this work was to provide a decision-support system to reduce the false positive cases sent to biopsy using a combination of negative follow-up and final pathology for all cases of negative or borderline (B1, B2, B3) VAB results.

5. Conclusions

In conclusion, we think that our preliminary results open the way to further research in radiomics of calcifications on DBT, in particular for reducing FP rate and improving the diagnostic confidence of suspected malignant patients with a risk stratification approach. This advantage seems to be particularly useful in our study for the borderline BI-RADS category as BI-RADS 3 and could be also for BI-RADS 4a in larger studies, providing suggestions to eventually consider the not immediate need of biopsy referral but alternative recall for low-risk patients. Increased sample size, integration with clinical as well as personal and history data may lead to increased performances of radiomic-base classifiers and DSS in this particular field.

Supplementary Materials: The following are available online at https://www.mdpi.com/2076-3417/11/6/2503/s1, Supplementary file S1: List, nomenclature and values of the 319 IBSI-compliant extracted radiomic features for a representative patient with malignant calcification, Supplementary file S2: List, nomenclature and values of the 150 IBSI-compliant stable radiomic features for a representative patient with malignant calcification.

Author Contributions: Conceptualization, N.C.D., M.A., D.F., C.S. and I.C.; methodology, M.A., D.F. and C.S.; software, C.S. and M.I.; validation, N.C.D., M.I.; formal analysis, N.C.D., C.S., M.M. and M.I.; investigation, N.C.D.; resources, N.C.D.; data curation, N.C.D. and S.S.; writing—original draft preparation, M.A., D.F., M.M., C.S., M.I. and I.C.; writing—review and editing, M.A., M.I. and S.S.; supervision, S.P. and I.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethical Committee of Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milan (protocol code Tomo-AI; protocol-ID 1666; approved on 14 October 2020).

Informed Consent Statement: Patient consent was waived by the Ethical Committee due to the retrospective nature of this study.

Conflicts of Interest: C.S. is CEO of DeepTrace Technologies S.R.L, a spin-off of Scuola Universitaria Superiore IUSS, Pavia, Italy. I.C. and M.I. own DeepTrace Technologies S.R.L shares. All other authors declare that they have no conflict of interest and that they have nothing to disclose.

Abbreviations

AUC Area Under the Curve
BC Breast cancer
DBT Digital breast tomosynthesis
FP False positive
FN False negative
IBSI International Biomarker Standardization Initiative
NPV  Negative predictive value
PPV  Positive predictive value
ROI  Region of interest
TP   True positive
TN   True negative
VAB  Vacuum-assisted biopsy

References
1. Narayan, A.K.; Keating, D.M.; Morris, E.A.; Mango, V.L. Calling all calcifications: A retrospective case control study. Clin. Imaging 2019, 53, 151–154. [CrossRef]
2. Oligane, H.C.; Berg, W.A.; Bandos, A.I.; Chen, S.S.; Sohrabi, S.; Anello, M.; Zuley, M.L. Grouped Amorphous Calcifications at Mammography: Frequently Atypical but Rarely Associated with Aggressive Malignancy. Radiology 2018, 288, 671–679. [CrossRef] [PubMed]
3. Dodelzon, K.; Simon, K.; Dou, E.; Levy, A.D.; Michaels, A.Y.; Askin, G.; Katzen, J.T. Performance of 2D Synthetic Mammography Versus Digital Mammography in the Detection of Microcalcifications at Screening. Am. J. Roentgenol. 2020, 214, 1436–1444. [CrossRef]
4. Schrading, S.; Distelmaier, M.; Dirrichs, T.; Detering, S.; Brolund, L.; Kuhl, C. Digital Breast Tomosynthesis–guided Vacuum-assisted Breast Biopsy: Initial Experiences and Comparison with Prone Stereotactic Vacuum-assisted Biopsy. Radiology 2014, 274, 654–662. [CrossRef]
5. Horvat, J.V.; Keating, D.M.; Rodrigues-Duarte, H.; Morris, E.A.; Mango, V.L. Calcifications at Digital Breast Tomosynthesis: Imaging Features and Biopsy Techniques. RadiGraphics 2019, 39, 307–318. [CrossRef] [PubMed]
6. Lang, K.; Negarden, M.; Andersson, I.; Rosso, A.; Zackrisson, S. False positives in breast cancer screening with one-view breast tomosynthesis: An analysis of findings leading to recall, work-up and biopsy rates in the Malmö Breast Tomosynthesis Screening Trial. Eur. Radiol. 2016, 26, 3899–3907. [CrossRef] [PubMed]
7. Gillies, R.J.; Kinahan, P.E.; Hricak, H. Radiomics: Images are More than Pictures, They are Data. Radiology 2016, 278, 563–577. [CrossRef] [PubMed]
8. Lambin, P.; Leijenaar, R.T.H.; Deist, T.M.; Peerlings, J.; de Jong, E.E.C.; van Timmeren, J.; Larue, R.T.H.M.; Even, A.J.G.; Jochems, A.; et al. Radiomics: The bridge between medical imaging and personalized medicine. Nat. Rev. Clin. Oncol. 2017, 14, 749–762. [CrossRef] [PubMed]
9. Rizzo, S.; Botti, F.; Raimondi, S.; Origgi, D.; Fanciullo, C.; Morganti, A.G.; Bellomi, M. Radiomics: The facts and the challenges of image analysis. Eur. Radiol. Exp. 2018, 2, 36. [CrossRef]
10. Gatta, R.; Depeursinge, A.; Ratib, O.; Michielin, O.; Leimgruber, A. Integrating radiomics into holomics for personalised oncology: From algorithms to bedside. Eur. Radiol. Exp. 2020, 4, 11. [CrossRef] [PubMed]
11. Sicilia, R.; Cordelli, E.; Merone, M.; Luperto, E.; Papalia, R.; Iannello, G.; Soda, P. Early Radiomic Experiences in Classifying Prostate Cancer Aggressiveness using 3D Local Binary Patterns. In Proceedings of the 2019 IEEE 32nd International Symposium on Computer-Based Medical Systems (CBMS), Cordoba, Spain, 5–7 June 2019; pp. 355–360.
12. Geras, K.J.; Mann, R.M.; M oy, L. Artificial Intelligence for Mammography and Digital Breast Tomosynthesis: Current Concepts and Future Perspectives. Radiology 2019, 182627. [CrossRef] [PubMed]
13. Tomosynthesis Use in Screening. Available online: https://healthcare-quality.jrc.ec.europa.eu/european-breast-cancer-guidelines/screening-tests (accessed on 1 February 2021).
14. Samala, R.K.; Chan, H.-P.; Lu, Y.; Hadijisski, L.M.; Wei, J.; Helvie, M.A. Digital breast tomosynthesis: Computer-aided detection of clustered microcalcifications on planar projection images. Phys. Med. Biol. 2014, 59, 7457–7477. [CrossRef] [PubMed]
15. Sahiner, B.; Chan, H.-P.; Hadijisski, L.M.; Helvie, M.A.; Wei, J.; Zhou, C.; Lu, Y. Computer-aided detection of clustered microcalcifications in digital breast tomosynthesis: A 3D approach. Med. Phys. 2011, 39, 28–39. [CrossRef] [PubMed]
16. Samala, R.K.; Chan, H.-P.; Hadijisski, L.M.; Helvie, M.A. Analysis of computer-aided detection techniques and signal characteristics for clustered microcalcifications on digital mammography and digital breast tomosynthesis. Phys. Med. Biol. 2016, 61, 7092–7112. [CrossRef]
17. Samala, R.K.; Chan, H.-P.; Lu, Y.; Hadijisski, L.M.; Wei, J.; Helvie, M.A. Computer-aided detection system for clustered microcalcifications in digital breast tomosynthesis using joint information from volumetric and planar projection images. Phys. Med. Biol. 2015, 60, 8457–8479. [CrossRef] [PubMed]
18. Wei, J.; Chan, H.-P.; Hadijisski, L.M.; Helvie, M.A.; Lu, Y.; Zhou, C.; Samala, R. Multichannel response analysis on 2D projection views for detection of clustered microcalcifications in digital breast tomosynthesis. Med. Phys. 2014, 41, 041913. [CrossRef] [PubMed]
19. Tagliafico, A.S.; Valdora, F.; Mariscotti, G.; Durando, M.; Nori, J.; La Forgia, D.; Rosenberg, I.; Caumo, F.; Gandolfo, N.; Houssami, N.; et al. An exploratory radiomics analysis on digital breast tomosynthesis in women with mammographically negative dense breasts. Breast 2018, 40, 92–96. [CrossRef] [PubMed]
20. Tagliafico, A.S.; Bignotti, B.; Rossi, F.; Matos, J.; Calabrese, M.; Valdora, F.; Houssami, N. Breast cancer Ki-67 expression prediction by digital breast tomosynthesis radiomics features. Eur. Radiol. Exp. 2019, 3, 36. [CrossRef]
21. D’Orsi, C.; Bassett, L.; Feig, S. Breast imaging reporting and data system (BI-RADS). Breast Imaging Atlas 2018.
22. Liberman, L.; Menell, J.H. Breast imaging reporting and data system (BI-RADS). *Radiol. Clin.* 2002, 40, 409–430. [CrossRef]
23. DeepTrace Technologies. Available online: http://www.deeptracetech.com/files/TechnicalSheet__TRACE4.pdf (accessed on 1 February 2021).
24. Zwanenburg, A.; Leger, S.; Vallières, M.; Löck, S. Image biomarker standardisation initiative-feature definitions. *arXiv* 2016, arXiv:1612.07003.
25. Zwanenburg, A.; Vallières, M.; Abdalah, M.A.; Aerts, H.J.W.L.; Andrareczyk, V.; Apte, A.; Ashrafinia, S.; Bakas, S.; Beukinga, R.J.; Boellaard, R.; et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. *Radiology* 2020, 295, 328–338. [CrossRef]
26. Haralick, R.M.; Shanmugam, K.; Dinstein, I. Textural Features for Image Classification. *IEEE Trans. Syst. Man Cybern.* 1973, SMC–3, 610–621. [CrossRef]
27. Thibault, G.; Fertil, B.; Navarro, C.; Pereira, S.; Cau, P.; Lévy, N.; Sequeira, J.; Mari, J.L. Texture Indexes and Gray Level Size Zone Matrix. Application to Cell Nuclei Classification. In Proceedings of the Pattern Recognition and Information Processing (PRIP), Minsk, Belarus, 19–21 May 2009; pp. 140–145.
28. Van Griethuysen, J.J.M.; Fedorov, A.; Parmar, C.; Hosny, A.; Aucoin, N.; Narayan, V.; Beets-Tan, R.G.H.; Fillon-Robin, J.C.; Pieper, S.; Aerts, H.J.W.L. Computational Radiomics System to Decode the Radiographic Phenotype. *Cancer Res.* 2017, 77, e104–e107. [CrossRef] [PubMed]
29. Valdora, F.; Houssami, N.; Rossi, F.; Calabrese, M.; Tagliafico, A.S. Rapid review: Radiomics and breast cancer. *Breast Cancer Res. Treat.* 2018, 169, 217–229. [CrossRef] [PubMed]
30. Conti, A.; Duggento, A.; Indovina, I.; Guerrisi, M.; Toschi, N. Radiomics in breast cancer classification and prediction. In *Seminars in Cancer Biology*; Academic Press: Cambridge, MA, USA, 2020.
31. Chen, S.; Guan, X.; Shu, Z.; Li, Y.; Cao, W.; Dong, F.; Zhang, M.; Shao, G.; Shao, F. A new application of multimodality radiomics improves diagnostic accuracy of nonpalpable breast lesions in patients with microcalcifications-only in mammography. *Med. Sci. Monit.* 2019, 25, 9786–9793. [CrossRef]
32. Mao, N.; Yin, P.; Li, Q.; Wang, Q.; Liu, M.; Ma, H.; Dong, J.; Che, K.; Wang, Z.; Duan, S.; et al. Radiomics nomogram of contrast-enhanced spectral mammography for prediction of axillary lymph node metastasis in breast cancer: A multicenter study. *Eur. Radiol.* 2020, 30, 6732–6739. [CrossRef] [PubMed]
33. Tan, H.; Wu, Y.; Bao, F.; Zhou, J.; Wan, J.; Tina, J.; Lin, Y.; Wang, M. Mammography-based radiomics nomogram: A potential biomarker to predict axillary lymph node metastasis in breast cancer. *Br. J. Radiol.* 2020, 93, 20191019. [CrossRef] [PubMed]
34. Zhang, F.; Wu, S.; Zhang, C.; Chen, Q.; Yang, X.; Jiang, K.; Zheng, J. Multi-domain features for reducing false positives in automated detection of clustered microcalcifications in digital breast tomosynthesis. *Med. Phys.* 2019, 46, 1300–1308. [CrossRef] [PubMed]